FDA advisory committee reviews SYD-101 atropine eye drops for pediatric myopia
An FDA advisory committee convened on October 30 to discuss SYD-101, a low-dose atropine eye drop for slowing pediatric myopia that the FDA declined to approve last year. The treatment met its primary endpoint in a phase 3 trial, but the FDA determined the overall results were insufficient for approval.
